ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · J Clin Oncol · 2026-07-14

Secondary analysis of TRIANGLE: in 511 younger, untreated mantle cell lymphoma responders on ibrutinib-containing therapy with or without ASCT, non-randomised rituximab maintenance was associated with longer 4-year PFS (85% v 73%; 90% v 75%) but more grade 3–5 infections.

Secondary analysisn = 511
Ladetto et al. Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial
Rheumatology · RMD Open · 2026-06-24

Network meta-analysis of 99 RCTs in rheumatoid arthritis: JAK inhibitors (HAQ MD −0.13) and IL-6 inhibitors (MD −0.13) reduced activity limitation more than TNF inhibitors; no other significant class differences in pain, fatigue or physical or mental health.

Meta-analysisn = 99 trials
van Esveld et al. Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses
Haematology · Haematologica · 2026-04-16

Phase 2 randomised non-comparative trial in 92 patients with relapsed/refractory follicular lymphoma, stopped early for slow accrual: CR at end of induction 11.4% with lenalidomide-rituximab vs 15.2% with added bendamustine; severe toxicity 6.8% vs 13.0%.

RCTn = 92
Kersten et al. Lenalidomide-rituximab or lenalidomide-rituximabbendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.